[7] The two agents operate through entirely distinct physiological pathways: Retatrutide targets incretin and glucagon signalling, with observed improvements in body weight and metabolic parameters in clinical trials
doi: 10.1111/j.1748-1716.2010.02150.x [DOI] [PubMed] [Google Scholar] 53
Regulatory & Legal Status Tesamorelin holds a regulatory status no other peptide in this comparison shares it is FDA-approved, but only for one specific indication: reducing excess visceral abdominal fat in HIV patients with lipodystrophy, administered under a licensed prescription as Egrifta
Whether you are looking to lose those last 10 pounds or are seeking a total health overhaul, the next generation of peptides offers a more tailored path than ever before
Then I end up getting a pager and getting some homies
Semaglutide mainly targets the GLP-1 receptor , while retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors